FBRX

Forte Biosciences, Inc. Common Stock

26.66

USD

FBRX Earnings Reports

Positive Surprise Ratio

FBRX beat 18 of 28 last estimates.

64%

Next Report

Date of Next Report

May 13, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$1.02

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q1 25 (Revenue/ EPS)

-25.55%

Forte Biosciences, Inc. Common Stock earnings per share and revenue

On Mar 26, 2026, FBRX reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -1.23 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q1 26, 4 analysts forecast an EPS of -1.02 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Forte Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Forte Biosciences, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Forte Biosciences, Inc. Common Stock's Q4 2025 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Forte Biosciences, Inc. Common Stock expected to report next?

The next earning report is scheduled for May 13, 2026.

What are the forecasts for Forte Biosciences, Inc. Common Stock's next earnings report?

Based on 4 analysts, Forte Biosciences, Inc. Common Stock is expected to report EPS of -$1.02 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.